Value through Innovation31 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
29.10.2014

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries

21.10.2014

Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments

- For Ex-US and Ex-UK Media Only
20.10.2014

Winners of the 2014 European PRRS Research Award announced

16.10.2014

Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis

 

- For media outside UK, US and Canada
30.09.2014

Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund

27.09.2014

Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

- For Ex-US and Ex-UK Media Only
27.09.2014

Boehringer Ingelheim’s afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer

- For Ex-US and Ex-UK Media Only
26.09.2014

Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung

- For media outside UK and US only
18.09.2014

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

- For Ex-US and Ex-UK Media Only
16.09.2014

Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study

- For Non-U.S. and Non-UK Media
10.09.2014

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

- For Non-U.S. and Non-U.K. Media
09.09.2014

Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting

- For Non-US and Non-UK Media
09.09.2014

Nintedanib* slowed disease progression in IPF independent of patients’ lung function impairment at baseline

- For media outside UK, US and Canada
08.09.2014

European Respiratory Society International Congress 2014
TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD

- For media outside the US, the UK and Canada
08.09.2014

Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care

 

- For Media outside the US, the UK & Canada only
02.09.2014

ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin

- Non-US/Non-UK/Non-Canadian Media
01.09.2014

Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention

- For Non-US/Non-UK/Non-Canadian Media
01.09.2014

Boehringer Ingelheim Animal Health sees freshly mixed swine vaccines as its way forward

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16